<DOC>
	<DOCNO>NCT02273726</DOCNO>
	<brief_summary>The purpose study determine whether roxadustat effective safe compare epoetin alfa maintenance treatment anemia stable hemodialysis peritoneal dialysis subject convert exist stable erythropoiesis stimulate agent treatment .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Roxadustat Treatment Anemia Stable Dialysis Subjects</brief_title>
	<detailed_description>This study consist three study period follow : 1 . Screening Period 6 week ( 8 week Mircera ) 2 . Treatment Period : minimum 52 week , maximum 3 year . 3 . A Follow-up period 4 week . A total 820 patient randomize 1:1 ratio receive either roxadustat Epoetin alfa ( Active Control ) open-label manner .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Subject age ≥ 18 year Subject receive adequate dialysis use modality dialysis endstage renal disease ≥ 3 month prior screen Subject receive IV SC ESA ≥ 8 week prior screen stable ESA ( ≤30 % change ) dose 4 week ( 8 week Mircera ) prior randomization Mean subject 's 3 recent Hb value must ≥ 9.0 g/dL ≤ 12.0 g/dL ; absolute difference ≤ 1.3 g/dL high low value Subject ferritin level ≥ 100 ng/mL screen Subject transferrin saturation ( TSAT ) level ≥ 20 % screen Subject serum folate level ≥ low limit normal ( LLN ) , Vitamin B12 level ≥ LLN Subject 's ALT AST ≤ 3x upper limit normal ( ULN ) , TBL ≤ 1.5x ULN screen Subject 's body weight 45 kg 160 kg . Subject receive RBC transfusion within 8 week prior randomization Subject know history myelodysplastic syndrome multiple myeloma Subject know inherited disease thalassemia sickle cell anemia know cause anemia chronic kidney disease . Subject know hemosiderosis , hemochromatosis , coagulation disorder , hypercoagulable condition Subject know chronic inflammatory disease could cause anemia Subject anticipate surgery expect cause blood loss Subject know gastrointestinal bleeding Subject history chronic liver disease ( eg , chronic infectious hepatitis , chronic autoimmune liver disease , cirrhosis , fibrosis liver ) Subject congestive heart failure ( NYHA Class III IV ) Subject heart attack , stroke , seizure , thrombotic/thromboembolic event ( eg , DVT pulmonary embolism ) within 12 week prior participate study Subject uncontrolled high blood pressure within 2 week prior participate study Subject history malignancy , except follow : cancer determine cured remission ≥5 year , curatively resect basal cell squamous cell skin cancer , cervical cancer situ , resect colonic polyp . ) Subject positive human immunodeficiency virus ( HIV ) , Hepatitis B surface antigen , antihepatitis C virus antibody Subject prior organ transplant ( explanted ) Subject follow know untreated condition ; proliferative diabetic retinopathy , diabetic macular edema , macular degeneration retinal vein occlusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Dialysis</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>peritoneal dialysis</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>End stage renal disease</keyword>
	<keyword>Stable Dialysis</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>erythropoiesis stimulating agent</keyword>
</DOC>